Paul Da Silva Jardine, PhD

Head of Drug Discovery

Paul brings deep experience in drug discovery to Foresite Capital. Previously, Paul was vice president for cardiovascular and metabolic diseases at Pfizer.  There he led teams that were responsible for the discovery and early development of over fifty clinical candidates across all areas of CVMD.  These clinical candidates ranged from the first, lasofoxifene, a Selective Estrogen Receptor Modulator for the prevention of osteoporosis that was approved by The European Medicines Agency, to one of the last, ertugliflozin, a SGLT2 inhibitor approved by the FDA and EMA in 2017.  In addition, two other candidates that were originally developed by his teams for human use were approved by the FDA for veterinary use.

In 2015, Paul cofounded and was chief scientific officer of Staten Biotechnology which developed an anti-ApoC-III monoclonal antibody for the treatment of coronary heart disease and hypertriglyceridemia. Paul designed and successfully executed the approach that combined modern antibody engineering with hijacking endogenous mechanisms for clearing APOC-III laden triglyceride rich lipoprotein particles. In 2017, Staten reached a buy-out option deal with Novo Nordisk worth up to $485M.

Highlights

  • BSc degree in chemistry from the University of Texas at Austin and a PhD in chemistry from Harvard University.  
  • Served as venture partner at Appletree Partners where he helped in the formation of two entities.
People